Efficacy of LGE-MRI-guided fibrosis ablation versus conventional catheter ablation of atrial fibrillation: The DECAAF II trial: Study design. Marrouche, N. F., Greene, T., Dean, J. M., Kholmovski, E. G., Boer, L. M., Mansour, M., Calkins, H., Marchlinski, F., Wilber, D., Hindricks, G., Mahnkopf, C., Jais, P., Sanders, P., Brachmann, J., Bax, J., Dagher, L., Wazni, O., Akoum, N., & Investigators, T. D. I. Journal of Cardiovascular Electrophysiology, 32(4):916–924, 2021. _eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1111/jce.14957
Efficacy of LGE-MRI-guided fibrosis ablation versus conventional catheter ablation of atrial fibrillation: The DECAAF II trial: Study design [link]Paper  doi  abstract   bibtex   
Introduction Success rates of catheter ablation in persistent atrial fibrillation (AF) remain suboptimal. A better and more targeted ablation strategy is urgently needed to optimize outcomes of AF treatment. We sought to assess the safety and efficacy of targeting atrial fibrosis during ablation of persistent AF patients in improving procedural outcomes. Methods The DECAAF II trial (ClinicalTrials. gov identifier number NCT02529319) is a prospective, randomized, multicenter trial of patients with persistent AF. Patients with persistent AF undergoing a first-time ablation procedure were randomized in a 1:1 fashion to receive conventional pulmonary vein isolation (PVI) ablation (Group 1) or PVI + fibrosis-guided ablation (Group 2). Left atrial fibrosis and ablation induced scarring were defined by late gadolinium enhancement magnetic resonance imaging at baseline and at 3–12 months postablation, respectively. The primary endpoint is the recurrence of atrial arrhythmia postablation, including atrial fibrillation, atrial flutter, or atrial tachycardia after the 90-day postablation blanking period. Patients were followed for a period of 12–18 months with a smartphone ECG Device (ECG Check Device, Cardiac Designs Inc.). With an anticipated enrollment of 900 patients, this study has an 80% power to detect a 26% reduction in the hazard ratio of the primary endpoint. Results and Conclusion The DECAAF II trial is the first prospective, randomized, multicenter trial of patients with persistent AF using imaging defined atrial fibrosis as a treatment target. The trial will help define an optimal approach to catheter ablation of persistent AF, further our understanding of influencers of ablation lesion formation, and refine selection criteria for ablation based on atrial myopathy burden.
@article{marrouche_efficacy_2021,
	title = {Efficacy of {LGE}-{MRI}-guided fibrosis ablation versus conventional catheter ablation of atrial fibrillation: {The} {DECAAF} {II} trial: {Study} design},
	volume = {32},
	issn = {1540-8167},
	shorttitle = {Efficacy of {LGE}-{MRI}-guided fibrosis ablation versus conventional catheter ablation of atrial fibrillation},
	url = {https://onlinelibrary.wiley.com/doi/abs/10.1111/jce.14957},
	doi = {10.1111/jce.14957},
	abstract = {Introduction Success rates of catheter ablation in persistent atrial fibrillation (AF) remain suboptimal. A better and more targeted ablation strategy is urgently needed to optimize outcomes of AF treatment. We sought to assess the safety and efficacy of targeting atrial fibrosis during ablation of persistent AF patients in improving procedural outcomes. Methods The DECAAF II trial (ClinicalTrials. gov identifier number NCT02529319) is a prospective, randomized, multicenter trial of patients with persistent AF. Patients with persistent AF undergoing a first-time ablation procedure were randomized in a 1:1 fashion to receive conventional pulmonary vein isolation (PVI) ablation (Group 1) or PVI + fibrosis-guided ablation (Group 2). Left atrial fibrosis and ablation induced scarring were defined by late gadolinium enhancement magnetic resonance imaging at baseline and at 3–12 months postablation, respectively. The primary endpoint is the recurrence of atrial arrhythmia postablation, including atrial fibrillation, atrial flutter, or atrial tachycardia after the 90-day postablation blanking period. Patients were followed for a period of 12–18 months with a smartphone ECG Device (ECG Check Device, Cardiac Designs Inc.). With an anticipated enrollment of 900 patients, this study has an 80\% power to detect a 26\% reduction in the hazard ratio of the primary endpoint. Results and Conclusion The DECAAF II trial is the first prospective, randomized, multicenter trial of patients with persistent AF using imaging defined atrial fibrosis as a treatment target. The trial will help define an optimal approach to catheter ablation of persistent AF, further our understanding of influencers of ablation lesion formation, and refine selection criteria for ablation based on atrial myopathy burden.},
	language = {en},
	number = {4},
	urldate = {2021-11-15},
	journal = {Journal of Cardiovascular Electrophysiology},
	author = {Marrouche, Nassir F. and Greene, Tom and Dean, J. Michael and Kholmovski, Eugene G. and Boer, Leonie Morrison-de and Mansour, Moussa and Calkins, Hugh and Marchlinski, Francis and Wilber, David and Hindricks, Gerhard and Mahnkopf, Christian and Jais, Pierre and Sanders, Prashanthan and Brachmann, Johannes and Bax, Jereon and Dagher, Lilas and Wazni, Oussama and Akoum, Nazem and Investigators, The DECAAF II},
	year = {2021},
	note = {\_eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1111/jce.14957},
	keywords = {cardiac magnetic resonance imaging, fibrosis-guided ablation, persistent atrial fibrillation},
	pages = {916--924},
}
Downloads: 0
About
Documentation
Keywords
Search
Users
Terms and Conditions of Use
Privacy Policy
Sitemap
© BibBase.org 2021